



SOLVAY

asking more from chemistry®

Q2 & H1 2016 RESULTS

*July 29
2016*

SAFE HARBOR

This presentation may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&D projects and other unusual items.

Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements

This document does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities.

FORENOTE

The results of former Cytec are consolidated in the Group's income and cash flow statements since January 1, 2016. Comparative information for the second quarter and first half year of 2015 is presented on an unaudited pro forma basis as if the acquisition of Cytec had taken place on January 1, 2015.

Besides IFRS accounts, Solvay also presents underlying Income Statement performance indicators to provide a more consistent and comparable indication of the Group's financial performance. The underlying performance indicators adjust IFRS figures for the non-cash Purchase Price Allocation (PPA) accounting impacts related to acquisitions, for the coupons of perpetual hybrid bonds, classified as equity under IFRS but treated as debt in the underlying statements, and for other elements that would distort the analysis of the Group's underlying performance.

The comments on the results are made on an underlying basis unless otherwise stated.

OVERVIEW

- **Transformation delivery**
- Financial highlights
- Priorities and outlook
- Annexes



SOLVAY

asking more from chemistry®

EXECUTING OUR PLAN



Q2 2016

- **Significant cash generation improvement**
- **Profit growth and record margin**
- **Sustained excellence efforts**
- **Accelerated synergies from Cytec**

Delivering on priorities



Q2 RESULTS

RECORD MARGIN & IMPROVED CASH GENERATION

EBITDA

8% ↗

- Pricing power ↗
 - Positive for 10 quarters in a row
- Volume ↗
 - Innovation-driven growth in Advanced Materials and solid growth in Performance Chemicals
 - Partially offset by oil & gas headwinds

**Record EBITDA
margin at 22%**

Free Cash Flow^[1]

27% ↗

- Higher profits
- Reduced CapEx
- Working capital discipline
- H1 free cash flow^[1]
of € 200 m, up by € 346 m

**Higher cash
conversion at >60%**

RECOGNITION OF SOLVAY'S ADVANCED MATERIALS

- **Solvay and Mubadala JV strategically positioned to supply advanced composite materials for Boeing 777X primary structures**
- **Solvay wins supplier excellence award from GKN Aerospace**



OVERVIEW

- Transformation delivery
- **Financial highlights**
- Priorities and outlook
- Annexes



SOLVAY

asking more from chemistry®

STRONG RESULTS

FINANCIAL HIGHLIGHTS Q2 2016

€2.9 bn

Net Sales

-6%

yoy

- ↗ Volume decrease in Advanced Formulations offset by other segments
- ↘ Forex impact on conversion
- ↘ Deflation impact on prices

€652 m

Underlying EBITDA

+8%

yoy

- ↗ Pricing power
- ↗ Fixed costs lower on Excellence and synergies delivery
- ↘ Forex impact on conversion
- ↗ Margin record at 22%

€223 m

Underlying net income

Group share

€216 m

In Q2 2015

- ↗ Operating profit
- ↘ Reduced scope discontinued operations (Inovyn)

€174 m

Free cash flow

Continuing operations

€137 m


in Q2 2015

- ↗ Reinforced working capital discipline
- ↗ Lower capex and higher EBITDA
- ↘ FCF discontinued operations nil

SALES DOWN DUE TO ADVERSE FOREX & DEFLATION

Net sales

in €m



→ Volumes up slightly

- ↘ Market contraction in Advanced Formulations' oil & gas market
- ↗ More than offset by solid growth in other segments

↘ Unfavorable conversion forex


- ↘ EUR appreciated vs most currencies
- ↘ Main impact from BRL conversion

↘ Lower prices

- ↘ Partial pass-through of lower raw material costs in deflationary market

RECORD EBITDA MARGIN UNDERPINNED BY EXCELLENCE AND SYNERGIES

Underlying EBITDA in €m




↗ **Pricing power** maintained in deflationary environment

↘ **Conversion forex** from appreciating EUR

↗ **Fixed costs** down, as excellence and synergies more than offset inflation and new capacity costs

↗ **Others** include growing contribution RusVinyl

MARKET CONTRACTION OIL & GAS MORE THAN OFFSET IN OTHER SEGMENTS



UNDERLYING NET INCOME REFLECTING HIGHER OPERATING PROFIT

Underlying P&L

in €m

(in € m)	Q2 2016	Q2 2015 pro forma	% yoy
Net sales	2,946	3,135	(6)%
EBITDA	652	603	8%
<i>EBITDA margin</i>	22%	19%	2.9pp
Depreciation & amortization	(199)	(191)	(4)%
EBIT	453	412	10%
Net financial charges	(119)	(116)	(3)%
Income taxes	(94)	(92)	(3)%
<i>Tax rate (ytd)</i>	29%	31%	(1.7)pp
Discontinued operations	-	33	n.m.
Non-controlling interests	(16)	(21)	23%
Net income, Solvay share	223	216	4%
(Adjustments)	(39)	(78)	51%
Net income, Solvay share, IFRS	185	138	34%


Underlying net income (Solvay share) up 4%

- ↘ Depreciation and net financial charges slightly up on growing business
- ↗ Underlying tax rate at 29% ytd vs 30% in full year 2015
- ↘ No contribution of discontinued operations, following European chlorovinyls transfer to Inovyn JV mid 2015


CASH CONVERSION IMPROVED DRIVEN BY HIGHER EBITDA AND LOWER CAPEX

Cash conversion [1]

$$\frac{\text{EBITDA} - \text{capex}}{\text{EBITDA}}$$



Capex
Continuing operations
in €m



→ 2016

Growth capex at >50% of total
~2/3rd in Advanced Materials

- Aerospace prepreg line in Germany
- Expansion of Adhesives for aerospace in the U.K.
- PEEK plant in US
- Fluoropolymer plant in China, phase 2

Supplemented by
maintenance capex excellence

Profit growth
Improved cash conversion


SUSTAINABLE IMPROVEMENT
IN FREE CASH FLOW

REINFORCED FOCUS LEADS TO SUSTAINABLE FREE CASH FLOW GROWTH

Underlying net debt [1]

evolution

in €m



Free cash flow of €174 m vs €137 m in 2015 for continuing operations

- Driven by higher EBITDA, lower capex and strict working capital management
- H1 FCF of continuing operations at €200 m, up €346 m

Focus on working capital management

- Seasonally higher H1 outflow reduced to €(296) m
- ➔ Q2 outflow up yoy due to measures to better phase payments over Q's

Financial payments seasonally higher in Q2


- ➔ Solvay final dividend
- ➔ Bond coupon payments front end-loaded

EFFECTIVE TREASURY MANAGEMENT LEADING TO REDUCED COST OF DEBT

Underlying debt^[1] evolution

in €bn

- EUR perpetual hybrid bonds
- USD bonds
- EUR bonds [2]
- Other debt
- Cash



Underlying

Net debt^[1]

31/12/2015

€6.6 bn

30/06/2016

€7.0 bn

Leverage^[3]

2.8x

2.9x



Baa2
negative outlook



BBB-
stable outlook

INVESTMENT GRADE

OVERVIEW

- Transformation delivery
- Financial highlights
- **Priorities and outlook**
- Annexes



SOLVAY

asking more from chemistry®

OUTLOOK REAFFIRMED FOR FY 2016



**EBITDA
to grow high single
digits**

**Free cash flow
to exceed €650 m**

OUR COMMITMENT

→ **Exceed expectations on Cytec synergies**

→ **Excellence & portfolio optimization continuing**

→ **Reinforced focus on cash generation**

→ **Attractive returns to shareholders**



INVESTOR RELATIONS CONTACTS



Maria Alcón-Hidalgo

+32 2 264 1984
maria.alconhidalgo@solvay.com



Jodi Allen

+1 (973) 357 3283
jodi.allen@solvay.com



Geoffroy Raskin

+32 2 264 1540
geoffroy.raskin@solvay.com



Bisser Alexandrov

+32 2 264 3687
bisser.alexandrov@solvay.com



NEXT EVENTS

**September 29
2016**

Capital
Markets Day,
London

**November 8
2016**

Q3 2016
results

**February 24
2017**

Q4 & FY 2016
results

**May 3
2017**

Q1 2017
results

**May 9
2017**

Annual general
meeting

ANNEXES

- **Additional Q2 2016 financial data**
- Forex sensitivity & other financial considerations
- Solvay general information





SOLVAY

asking more from chemistry®


ADVANCED MATERIALS Q2 2016

INNOVATION & EXCELLENCE OVERCOME HEADWINDS

Net sales (in € m)



EBITDA (in € m)



Specialty Polymers' sales in other markets offset smart devices

- Good demand in automotive, healthcare, and consumer goods markets
- Smart devices sales impacted by destocking

Composite Materials preparing for new program ramp-ups

- Aircraft backlog remains strong
- Growth in new programs not yet offsetting demand decline in business jet & rotorcraft markets

Special Chem strong volumes

- Good demand from automotive catalysts
- Ramp-up of high-purity H₂O₂ units for use in semiconductor industry
- Scope effect from sale of refrigerants & PCC business in 2015



Silica business intrinsically flat

- Good market conditions in Europe/Americas
- Weaker market conditions in Asia
- Forex impact from devaluation of Venezuelan bolivar


ADVANCED FORMULATIONS Q2 2016

OIL & GAS HEADWINDS MASK OTHER MARKET GROWTH

Net sales (in € m)



EBITDA (in € m)



O&G weighs on **Novocare**, more than offsetting growth in other markets

- Sales down (17)% yoy due to O&G headwinds
- Rig count stabilized toward end of Q2
- Innovation-driven growth in coatings and agro partially mitigated impact
- Operational excellence measures helped sustain margins

Technology Solutions stable performance despite mining industry challenges

- Lower Cu & Al prices driving curtailments at existing mines; new mine projects are delayed
- Focus on managing costs through challenging times



Price pressure pushes **Aroma Performance** sales down

- Volume growth in vanillin formulations
- Price pressure continues, especially in monomer inhibitors

PERFORMANCE CHEMICALS Q2 2016

DEMAND IMPROVEMENT DRIVES GROWTH

Net sales (in €m)



EBITDA (in €m)



Soda Ash & Derivatives

- Demand returned for Europe & seaborne markets resulting in sales growth
- Bicarbonate sales increased as result of Thailand plant ramp up
- Gain of € 11 m on sale of surplus assets

Peroxides Stable performance

- Higher sales for traditional wood pulp bleaching offset lower sales in specialties
- Good global demand

Volume recovery in Acetow's market

- Sustained recovery in market continues (with the exception of China) resulting in good volume growth


Coatis remains challenged

- Conditions in Latin America affecting volumes and prices


FUNCTIONAL POLYMERS Q2 2016

EXCELLENCE-DRIVEN PROFIT GROWTH & RUSVINYL UP

Net sales (in €m)



EBITDA (in €m)



Chlorovinyls up thanks to RusVinyl

- Solid contribution from RusVinyl JV (Russian operations), operating at close to full capacity
- Higher PVC sales volumes offset by caustic soda production in VinyThai (Thai operations)
- Cost improvement measures supported EBITDA growth


Polyamide

- Demand satisfactory
- Planned maintenance turnaround impacted margins

CORPORATE & BUSINESS SERVICES Q2 2016

COST DISCIPLINE MAINTAINED

EBITDA (in € m)



Difficult business conditions for **Energy Services** with low energy & CO₂ prices

- Trading conditions in energy and carbon management services at low level
- Investments in biomass & biocoal-based energy plants proved more challenging

Other Corporate & Business Services benefited from cost improvement programs and Cytec synergy delivery

IFRS NET INCOME REFLECTING HIGHER OPERATING PROFIT

Underlying P&L

in € m

	Q2 2016	Q2 2015 pro forma	% yoy
Net income, Solvay share	223	216	4%
(Adjustments)	(39)	(78)	51%
PPA impact	(68)	(72)	
Other legacy costs related to changes in portfolio (e.g. retention premiums) [1]	(3)	(3)	
Net financial charges and remeasurements of equity book value of the RusVinyl joint venture	5	(4)	
Non-recurring items	(22)	(47)	
Impact portfolio management	(7)	(33)	
Remediation & litigation	(15)	(14)	
(Financial adjustments)	34	29	
(Tax adjustments)	99	20	
Discontinued operations	(7)	(1)	
Non-controlling interests adjustments	2	-	
(Other adjustments)	(87)	(4)	
Net income, Solvay share, IFRS	185	138	34%


IFRS net income (Solvay share) up 34%

- € (68) m PPA impact, entirely from amortization of intangibles
- € (7) m portfolio management & reassessments, mainly:
 - € (43) m restructuring costs
 - € 33 m one-off gains, mainly release to Solvay of Chemlogics holdback payments
 - € (4) m reversal on impairments R&I
- Exclusion of € (28) m hybrid debt coupons in net financial charges

WORKING CAPITAL MANAGEMENT COMPENSATES FOR HIGHER NEEDS OF SPECIALTY BUSINESSES

Net working capital [1]

% of total sales



→ H1 2016 inflated for 2.8% by receivable on Inovyn exit price

→ Working capital management efforts offset higher working capital needs of increasing share of specialty businesses in portfolio

- Higher growth profile
- Cytec acquisition

Committed to further optimization

DEBT PROFILE

BALANCED MATURITIES ALLOWING FLEXIBILITY



Major debt

31/12/2015

30/06/2016

	Face value	Average duration	Average cost	Face value	Average duration	Average cost
EUR bonds ^[1]	3,550	4.1	2.88%	2,750	4.8	2.07%
EUR perpetual hybrid bonds ^[2]	2,200	6.1	5.07%	2,200	5.6	5.07%
USD bonds	2,142 ^[3]	7.5	4.03%	2,101 ^[3]	7.0	4.03%
Total major debt	7,892	5.6	3.80%	7,051	5.7	3.59%

in € m

in years


in € m

in years

NET PENSION LIABILITIES ^[1] UP ON LOWER DISCOUNT RATES

Pensions (30/06/2016)

in €bn



Net pension liabilities increase at €3.2 bn


- Pension liabilities up to € (6.1) bn following discount rates drop after Brexit vote
- Pension assets stable at € 2.9 bn

Cash contribution of €(49) m in Q2 2016
(vs €42m in Q2 2015 excluding Cytec)

Net pension liabilities

(30/06/2016)

in €bn



Discount rate evolution ^[2]

Currency	30/06/2016	31/12/2015	Change
EUR	1.25%	2.25%	(1) pp
GBP	2.75%	3.75%	(1) pp
USD	3.75%	4.25%	(0.5) pp

All presented figures are for continuing operations only

ANNEXES

- Additional Q2 2016 financial data
- **Forex sensitivity & other financial considerations**
- Solvay general information



SOLVAY

asking more from chemistry®

UNDERLYING EBIT(DA) CONSIDERATIONS FOR 2016

Excellence

- Excellence programs on course to reach target
 - €800 m cumulative by YE16 vs 2013 cost base
 - > €600 m delivered in 2014-2015
- Cytec integration synergies
 - Cost savings estimated > €100 m by 2018
 - Revenue synergies on top

Depreciation & amortization

- Underlying depreciation & amortization expected at ~€(800) m (excluding PPA amortization)
- PPA amortization of ~€(370) m, consisting of PA impacts from Rhodia, Cytec and other smaller acquisitions (e.g. Chemlogics, Ryton)

Scope effects

- Acquisitions in 2015
 - Cytec full consolidation as of January 1, 2016
 - Small acquisition in 2015: EPIC
- Divestments in 2015
 - Refrigerants in May 2015: net sales of ~€50 m in 2014
 - PCC in November 2015: net sales of ~€60 m in 2014

OTHER EBIT(DA) CONSIDERATIONS FOR 2016

Forex sensitivity

- Immediate impact on conversion exposure
- Deferred transactional impact due to hedging (6-12 month rolling basis)
- Mainly linked to USD
 - Sensitivity in 2016:
 - ~ € 120 m REBITDA per (0.10) \$/€
 - ~60% conversion, ~40% transactional
- Other forex exposures
 - JPY, CNY, THB, BRL, KRW, RUB
- Total conversion impact on underlying EBITDA of € (26) m in H1 2016, vs. € 100 m in H1 2015.
- Evolution of main currencies Solvay is exposed to:

/€	USD	JPY	BRL	RUB	CNY	KRW	THB
H1 2016	1.116	124	4.13	78.39	7.29	1319	39.55
H1 2015	1.115	134	3.31	64.59	6.94	1226	36.76
Change	0.0%	-7.2%	24.9%	21.4%	5.2%	7.5%	7.6%

As of end of Jun30, Source ECB

Underlying adjustments to IFRS figures

- To improve comparability of results over periods
- Exclusion of
 - Amortization of PPA and inventory step-up from acquisitions
 - Impact of portfolio management and reassessments
 - Legacy remediation and major litigations
 - Exceptional financial elements, such as hyperinflation
 - Impact of change in rates on discounting charges
 - Tax impacts related to previous periods
 - Valuation impacts of discontinued operations
- Reclassification of
 - Coupons of perpetual hybrid bonds as net financial charges (considered as equity under IFRS)
 - Financial charges RusVinyl as net financial charges (only realized gains/losses)
- Impact of the above on tax and share of non-controlling interests

UNDERLYING FINANCIAL & TAX CONSIDERATIONS IN 2016

Cost of borrowings

Total underlying financial charges expected at ~€ (350) m (incl. perpetual hybrid bonds)

- Financial charges from major senior debt (excl. perpetual hybrid bonds)
 - 2016 charges expected at ~€ (150) m
 - At end Q2'16, average cost 2016 is 2.9% (2015: 5.2%) vs 3.3% before reimbursement of EIB loan of € 300 m reimbursed in January and € 500 m hybrid bond in June 2016.
- Coupons from perpetual hybrid bonds (considered as Dividend & Equity under IFRS)
 - 2016 cash out of € (84) m: Q2 € (57) m / Q4 € (27) m
 - From 2017 onwards € (112) m: Q2 € (84) m / Q4 € (27) m

➔ Average cost : 5.1%
- Other elements ~€ (90-100) m
 - Currency swaps & Other debt in consolidated subsidiaries
 - Financial charges RusVinyl ^[2]: ~€ (25) m

Discounting of pensions and HSE

- P&L: ~€ (100) m (³/₄ - pensions, ¹/₄ - HSE)
- Sensitivity to change in discount rates ^[1]: ~€ (360) m / 50bp
 - Pensions (in OCI)
 - €-zone ~€ (140) m
 - USA ~€ (80) m
 - UK ~€ (120) m
 - Others ~€ (10) m
 - HSE (in P&L): €-zone ~€ (10) m

Tax rate

Underlying tax rate (adjusted for PPA and other factors) expected stable in the low ~30s

OTHER CONSIDERATIONS FOR 2016

Discontinued operations

- Indupa chlorovinyls business in Latin America
 - Agreement reached on 02/05/2016 to sell to Brazilian chemical group Unipar Carbocloro for EV of US\$ 202 m, subject to closing conditions
 - ~€ (50) m in CTA to be recycled through P&L at exit
- European chlorovinyls until June 30, 2015
 - Now part of Inovyn JV

Cash flow elements

- Cash expenses for pensions: € (180) m - € (200) m
- Capital expenditure: ~€ 950 m

Inovyn JV

- Beginning of July 2016, Solvay has completed the divestment of its shareholding in Inovyn, bringing to an end its chlorovinyls joint venture with Ineos.
- Solvay received exit cash proceeds amounting to €335 million.

ANNEXES


- Additional Q2 2016 financial data
- Forex sensitivity & other financial considerations
- **Solvay general information**



SOLVAY

asking more from chemistry®

SOLVAY GROUP IN TRANSFORMATION




FURTHER UPGRADE TO COME FROM DIVESTITURES

DIVERSIFIED & RESILIENT MARKET EXPOSURE

Balanced regional profile



Diversified & higher growth end-markets



30,910

employees



53

countries



145


industrial sites



21

main R&I centers

ALIGNED BUSINESS SEGMENTS STRATEGICALLY COHERENT TO DRIVE RESULTS



GROWTH ENGINES

ADVANCED MATERIALS

High performance materials, providing solutions for sustainable mobility: **light-weighting**, CO₂ and energy efficiency

Specialty Polymers **#1**

Composite Materials **#2**

Special Chem **#1**

Silica **#1**

ADVANCED FORMULATIONS

Customized specialty formulations in **surface chemistry**, optimizing efficiency, minimizing environmental impact

Novecare **#1**

Technology Solutions **#1**

Aroma Performance **#1**

RESILIENT CASH CONTRIBUTOR

PERFORMANCE CHEMICALS

Leading positions in chemical intermediates, through scale and technology

Soda Ash & Derivatives **#1**

Peroxides **#1**

Acetow **#4**

Coatis **#1**

FUNCTIONAL POLYMERS

Leading regional positions in functional polymers, with focus on excellence

Polyamide **#3**

Chlorovinyls **#2**

Market positions:

- #X** Global market position in main markets addressed
- #X** Regional market position in main markets addressed

2015 pro forma GROUP

Net sales **€ 12,378 m**
REBITDA **€ 2,336 m**
margin **19%**
CFROI **6.1%**

€ 4,503 m

€ 1,079 m

24%

8.2%

€ 2,855 m

€ 522 m

18%

5.7%

€ 3,052 m

€ 770 m

25%

8.5%

€ 1,926 m

€ 190 m


10%

3.5%

UNIQUE LIGHTWEIGHTING OFFERING DRIVING SUSTAINABLE MOBILITY

Solvay's unique portfolio

Driving sustainable mobility



		AUTOMOTIVE	AEROSPACE
Applications	Current <input checked="" type="checkbox"/>	Under the hood <input checked="" type="checkbox"/>	Primary structure <input checked="" type="checkbox"/>
	Future <input type="checkbox"/>	Battery tray <input checked="" type="checkbox"/>	Secondary struct. <input checked="" type="checkbox"/>
		Upperbody/hood <input type="checkbox"/>	Jet engines <input checked="" type="checkbox"/>
		Chassis <input type="checkbox"/>	Cabin interior <input checked="" type="checkbox"/>
Customers & collaborations		<p>Most major OEMS worldwide</p>	<p>BOEING LOCKHEED MARTIN AIRBUS BOMBARDIER SAFRAN</p>

PROVIDING SOLUTIONS

- Lightweight materials for transportation
- Production cycle time acceleration
- Total cost reduction

UNDERPINNED BY

- Reduction of fuel consumption
- Decreasing CO₂ emissions
- Increasing driving autonomy

Supported by regulatory framework for cleaner vehicles (aeronautics in discussion)

BROAD OFFERING OF INNOVATIVE FORMULATIONS MODIFYING SURFACE CHEMISTRY & FLUID BEHAVIORS



NEXT GENERATION
SOLUTIONS FOR HOME
FABRIC & PERSONAL
CARE



IMPROVED RECOVERY
AND YIELD

COMPETITIVE technology portfolio

- Leader in global markets & niche specialty technologies:

MILD SURFACTANTS	NATURAL (GUAR) & SYNTHETIC POLYMERS	PHOSPHINES
---------------------	---	------------



ENHANCED EFFICIENCY
FERTILIZERS

- Supplying OEMs, Tier 1 B2B and global B2C brand-owners
- Highly competitive global on-pipe alkoxylation footprint

REDUCED environmental impact



COST EFFICIENT
FRICTION REDUCERS

USING CUSTOMER INTIMACY & MARKET FOCUS AS CRITICAL SUCCESS FACTORS

COMMITTED TO SUSTAINABILITY



SOLVAY

Contribute to Society

Innovate

Sustainable solutions

Light-weighting materials
Sustainable energy
Ecofriendly materials

Air and water care
Smart and efficient processes

Act

Responsibly

Operating responsibly

Empowering people

SOCIETAL ACTIONS

x2

Employees involved in societal actions

SPM

50%

Share of sustainable solutions in the Group portfolio

SOLVAY'S COMMITMENT BY 2025 VS YE 2014

PEOPLE MANAGEMENT

80%

Employee engagement index

CO₂

-40%

Reduction of carbon intensity

SAFETY

-50%

of occupational accidents with MTAR target < 0.50





SOLVAY

asking more from chemistry®